Our research has been published in “Experimental and therapeutic medicine” cited at PubMed Central, US National Library of Medicine, National Institutes of Health; “CellR4”, the official journal of The Cure Alliance...
Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board...
Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions.
Cultured Wharton's Jelly, along with stem cell therapies derived from umbilical cord blood and adipose tissue, are showing promise in clinical trials for treating various medical conditions, such as osteoarthritis, spinal cord injury, and heart disease.
The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood)...
Stem cells are essentially “blank slate” cells that possess the remarkable potential to differentiate to any one of the billions of cells that form the diverse tissues of the human body. Stem cells have the power to divide virtually without limits and convert or develop into specialized cells that can replace injured or damaged tissue. Additionally, stem cells are known to secrete cytokines (small secreted proteins released by cells) that have immunomodulatory effects that have been demonstrated to exert a therapeutic effect. Stem cells have been shown to migrate to sites of injury and inflammation where they are believed to support the survival of damaged cell and inhibit the immune responses. Tissue-specific stem cells (“adult” or “somatic” stem cells), are already specialized and can produce different cell types for the specific tissue or organ in which they reside. Stem cell research is the most exciting option in the field of regenerative medicine being tested for efficacy in treating a variety of health issues where the body’s own response to traditional treatment isn’t sufficient to restore health and optimum function. Stem cell application in clinical trials shows promising results in therapy of neurological, musculoskeletal, cardiovascular and metabolic diseases. Stem cell therapies and regenerative medicine are becoming the preferred substitutes for many surgical, pharmacological, and rehabilitative medical services.
Explore the power of stem cells in treating various medical conditions.
Human Umbilical cord blood (hUCB)
Adipose Tissue derived stem cell
BHI Stem Cells has taken every precaution to ensure the safety and viability of administered stem cells. BHI stem cells are tested for sterility, infectious diseases and have high cell count and viability. Every unit of Human Umbilical Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells has the Cell Quality Certificate with the following information: Virus Tests (Hepatitis B virus, Hepatitis C virus, Human Immunodeficiency virus and Treponema pallidum), Microbiological Tests (Bacteria, Fungus, Mycoplasma, Endotoxin), the cell count and viability.
Cell Quality Certificate for Human Umbilical Cord Blood Mononuclear Cells
Issued Aug 2022View Certificate
Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic InflammationView Research
A Clinical Trial Report of Autologous Bone Marrow Derived Mesenchymal Stem Cell Transplantation in Patients with Spinal Cord InjuryView Research
Allogeneic umbilical cord blood mononuclear cell therapy for spinal cord injuryView Research
A Retrospective Study of Stromal Vascular Fraction Cell Therapy for OsteoarthritisView Research
Case Series: Dendritic Cell- Cytokine Induced Killer Cell Therapy in Subjects with Chronic Lymphocytic Leukemia and Peritoneal CancerView Research
Evaluation of Immune response to Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic InflammationView Research
This original clinical study article describes the use and safety of umbilical cord wharton’s jelly derived-mesenchymal stem cell therapy for a range of indications.View Research
Hundreds of allogeneic stem cell therapies are underway in humans for a wide-range of medical conditions. However, these studies are not always following regulatory compliances; accordingly they have not been proven to be safe. BHI Stem Cells has unique advantages over its competitors. We are in regulatory compliance in each country we conduct clinical trials to ensure the lab and clinical procedures are lawfully approved by their federal agencies. Based on our nonclinical and pilot clinical study results, showing the safety of our hUCB product, we are planning to start IND clinical trials. FDA endorsed our Investigator-led IND (Investigational New Drug) application to allow for initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. This prospective, open-label, single-center, exploratory clinical study is designed to characterize the safety and efficacy profile of HCP, cord blood, when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke. Intravenous infusion of HCP, cord blood, in conjunction with mannitol, will be used in instances where a subject is unable to tolerate intrathecal administration.
In specific markets around the world, there is both the unmet need and the financial opportunity to establish medical facilities that provide the same quality as that found in the best facilities in the United States. BHI Stem Cells believes it is uniquely positioned to become a leader in providing the highest quality cellular therapies through centers it intends to locate throughout the world. BHI Stem Cells has recruited top medical professionals and scientific advisors, and regulatory specialists to help determine the best possible procedures to offer, to provide the appropriate protocols to monitor safety and efficacy, to collect and analyze outcome data for potential submission to the FDA and EMA, and to innovate patent procedures, devices, and therapies for future commercialization.